US stocks drift ahead of Tuesday's jobs report
THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.
The S&P 500 slipped 0.2%, even though a slight majority of stocks within the index rose. The Dow Jones Industrial Average was down 75 points, or 0.2%, as of
Helping to keep the market in check were stocks in the artificial-intelligence industry, which were mixed following their scary swings last week.
But Oracle sank another 2.6% following its 12.7% tumble last week, which was its worst in more than seven years.
AI stocks have been shaky on worries that the billions of dollars flowing into chips and data centers may not produce a big-enough payoff to make it worth it. The doubts are causing cracks for the industry, whose earlier surges was the main driver for the
Besides AI, the main focus on
On Tuesday will come the jobs report for November, and economists expect it to show employers added 40,000 more jobs than they cut during the month. Thursday will bring an update on the inflation, and economists expect it to show
Such data is under the microscope because the
The hope on
“With the Fed still appearing to be more focused on labor-market weakness than inflation, we’re likely facing a ‘bad news is good’ scenario for the jobs report,” according to
“As long as the numbers don’t suggest employment is falling off a cliff,” that would mean the market would likely welcome soft numbers, he said.
The spotlight will be brightest on the unemployment rate, not the overall job growth numbers, because the latter is feeling downward pressure from a drop-off in immigrant workers. Economists expect Tuesday’s report to show the unemployment rate at 4.4%, which would keep it near its highest and worst level since 2021.
The yield on the 10-year
Elsewhere on
In stock markets abroad, indexes rose in
Indexes fell 1.3% in
Japan’s
___
AP Business Writer


Legislation introduced to extend national flood insurance program
Report Summarizes Kinase Inhibitors Study Findings from Saga University Hospital (Simulation of Perioperative Ibrutinib Withdrawal Using a Population Pharmacokinetic Model and Sparse Clinical Concentration Data): Drugs and Therapies – Kinase Inhibitors
Advisor News
- Global economic growth will moderate as the labor force shrinks
- Estate planning during the great wealth transfer
- Main Street families need trusted financial guidance to navigate the new Trump Accounts
- Are the holidays a good time to have a long-term care conversation?
- Gen X unsure whether they can catch up with retirement saving
More Advisor NewsAnnuity News
- Prudential launches FlexGuard 2.0 RILA
- Lincoln Financial Introduces First Capital Group ETF Strategy for Fixed Indexed Annuities
- Iowa defends Athene pension risk transfer deal in Lockheed Martin lawsuit
- Pension buy-in sales up, PRT sales down in mixed Q3, LIMRA reports
- Life insurance and annuities: Reassuring ‘tired’ clients in 2026
More Annuity NewsHealth/Employee Benefits News
Life Insurance News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on Malaysia’s Non-Life Insurance Segment
- Report Summarizes Kinase Inhibitors Study Findings from Saga University Hospital (Simulation of Perioperative Ibrutinib Withdrawal Using a Population Pharmacokinetic Model and Sparse Clinical Concentration Data): Drugs and Therapies – Kinase Inhibitors
- Flawed Social Security death data puts life insurance benefits at risk
- EIOPA FLAGS FINANCIAL STABILITY RISKS RELATED TO PRIVATE CREDIT, A WEAKENING DOLLAR AND GLOBAL INTERCONNECTEDNESS
- Envela partnership expands agent toolkit with health screenings
More Life Insurance News